About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and ...

Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to ...

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is redefining what it means to ...

FORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- LQpay today announced the launch of Agentic AI API, a proprietary healthcare interoperability platform that enables human-like interaction with ...

(Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced positive topline results from its Phase ...

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), ...

In preclinical studies, ABP-102 / CT-P72 demonstrated robust antitumor activity in HER2-high tumor models, including dual xenograft models containing both HER2-high and HER2-low tumors, with selective ...

Alesta Therapeutics, a biotechnology company focused on developing transformative small-molecule therapies for underserved diseases, provided a corporate and clinical update in advance of its ...

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that ...

Fischer Imaging intends to raise the capital needed to seek regulatory clearance and prepare for commercialization of MammoCAT in 2026. The company will present at RESI JPM 2026 Innovator’s Pitch ...

“The dosing of the first human subject using our novel formulation technology platform is yet another significant milestone for our company as we continue to advance our pipeline of innovative, ...

Aclarion believes the continued expansion of high-quality clinical sites, combined with early surgical throughput, positions CLARITY to progress with increasing efficiency and predictability, ...